Daniel M. Miller

Daniel M. Miller

Auto-generated profile, based on publicly available information

Daniel M. Miller

Cincinnati Eye Institute, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Ophthalmology
Verified
Journal Article
Open access
NHNancy M. Holekamp
Nancy M. Holekamp
PCPeter A. Campochiaro
Peter A. Campochiaro
MCMargaret A. Chang
Margaret A. Chang
DMDaniel Miller
Daniel Miller
DPDante Pieramici
Dante Pieramici
CRCarl Regillo
Carl Regillo
To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD). Phase 3, open-label, randomized, visual acuity assessor-masked noninferiority and equivalence trial. Patients with nAMD diagnosed within 9 months of screening previously treated with and responsive to anti-vascular endothelial growth factor therapy. Patients were randomized 3:2 to treatment with the PDS with ranibizumab 100 mg/ml with fixed 24-week (Q24W) refill-exchanges (PDS Q24W) or intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab). Primary end point was change in best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter (letters) score from baseline averaged over weeks 36 and 40 (noninferiority margin,-4.5 letters; equivalence margin, ±4.5 letters). Archway enrolled 418 patients; 251 were randomized to and 248 received treatment with the PDS Q24W, and 167 were randomized to and received treatment with monthly ranibizumab. Baseline BCVA was 74.4 letters (PDS Q24W arm) and 75.5 letters (monthly ranibizumab arm; Snellen equivalent, 20/32). Adjusted mean change in BCVA score from baseline averaged over weeks 36 and 40 was +0.2 letters (standard error [SE], 0.5 letters) in the PDS Q24W arm and +0.5 letters (SE, 0.6 letters) in the monthly ranibizumab arm (difference, -0.3 letters; 95% confidence interval, -1.7 to 1.1 letters). PDS Q24W was both noninferior and equivalent to monthly ranibizumab. Of 246 PDS-treated patients assessed for supplemental ranibizumab treatment, 242 (98.4%) did not receive supplemental ranibizumab treatment before the first refill-exchange procedure, including 4 patients who discontinued treatment before the first refill-exchange procedure. Prespecified ocular adverse events of special interest were reported in 47 patients (19.0%) in the PDS Q24W arm and 10 patients (6.0%) in the monthly ranibizumab arm, which included, in the former arm, 4 (1.6%) endophthalmitis cases, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, and 5 (2.0%) conjunctival retractions. Most ocular adverse events in the PDS Q24W arm occurred within 1 month of implantation. Archway met its primary objective and PDS Q24W demonstrated noninferior and equivalent efficacy to monthly ranibizumab, with 98.4% of PDS-treated patients not receiving supplemental treatment in the first 24-week interval.

1 May 2012 in Retina
Verified
Journal Article
Closed access
AMAmina I. Malik
Amina I. Malik
RFRobert E. Foster
Robert E. Foster
ZCZelia M. Correa
Zelia M. Correa
MPMichael R. Petersen
Michael R. Petersen
DMDaniel M. Miller
Daniel M. Miller
CRChristopher D. Riemann
Christopher D. Riemann
The purpose of this study was to report the observed outcomes of anticoagulated patients undergoing transconjunctival sutureless vitrectomies using subconjunctival anesthesia without preoperative cessation of anticoagulation and antiplatelet (AC/AP) agents. A retrospective chart review was performed on patients taking AC/AP agents who were undergoing transconjunctival sutureless vitrectomies with subconjunctival anesthesia between January 2007 and June 2009. Intra- and postoperative complications (such as massive hemorrhage), anatomical results, satisfactory analgesia (informed by patients and recorded by surgeon), anatomical results, and visual acuity were documented. Sixty-three surgeries were performed on 56 eyes of 52 patients. Thirty-two patients were taking aspirin and clopidogrel, 18 were taking warfarin, 5 were taking clopidogrel, 3 were taking aspirin and warfarin, 2 were taking acetylsalicylic acid and dipyridamole, and 1 was taking warfarin and clopidogrel. All patients had satisfactory analgesia. No intraoperative complications occurred. Seven eyes (13%) had postoperative vitreous hemorrhage. Overall, 79% of patients had improved postoperative visual acuity, 16% of patients had unchanged visual acuity, and 5% of patients had worse visual acuity at last follow-up visit. Medical disease requiring systemic AC/AP therapy is often present in patients with vitreoretinal disease. Transconjunctival sutureless vitrectomies using subconjunctival anesthesia may be a safe and effective surgical option in select patients in whom cessation of AC/AP and/or delayed ophthalmic intervention is imprudent.

11 August 2023 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Closed access
JEJared J. Ebert
Jared J. Ebert
YSYevgeniy (Eugene) Shildkrot
Yevgeniy (Eugene) Shildkrot
AMAlicia Menezes
Alicia Menezes
DMDaniel M. Miller
Daniel M. Miller
Purpose: To describe the surgical technique and long-term outcomes of a modified split-thickness corneal patch grafting for conjunctival erosions that can be seen in patients with the Port Delivery System (PDS) implant. Methods: By way of retrospective review of medical records, this interventional case series identified 2 cases in which modified split-thickness corneal patch grafting was used to repair conjunctival erosion in patients with the PDS implant. Results: The surgical approach involved creating a small opening in the corneal graft over the center of the PDS implant to improve visibility and allow for easier access during subsequent refill-exchange procedures. At the last follow-up of 6.9 years and 5.6 years, there was no recurrence of conjunctival erosions in either patient. The PDS implants remained well covered with the split-thickness corneal graft and had undergone multiple implant refills without complication or difficulty. Conclusions: Modified split-thickness corneal patch grafting with central graft aperture offers another option for long-term successful management of conjunctival erosions in patients with a PDS, especially those who have failed prior repair, by allowing sufficient visibility and access for subsequent refill-exchange procedures.

1 August 2022 in Retina
Verified
Journal Article
Closed access
NDNicholas E. Ba Dudenhoefer
Nicholas E. Ba Dudenhoefer
CNCarl W. Do Noble
Carl W. Do Noble
MPMichael R. Petersen
Michael R. Petersen
RFRobert E. Foster
Robert E. Foster
CRChristopher D. Riemann
Christopher D. Riemann
DMDaniel M. Miller
Daniel M. Miller
Purpose: To assess the long-term efficacy of intravitreal antivascular endothelial growth factor injections (IVI), alone or in combination with verteporfin photodynamic therapy (IVI/PDT), for management of choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome (POHS). Methods: Retrospective, comparative, interventional case series analyzing 82 eyes in 74 patients treated with either IVI or IVI/PDT for presumed ocular histoplasmosis syndrome choroidal neovascularization from January 2006 to January 2021. Results: The average logarithm of the minimum angle of resolution VA in year 5 was 0.40 (20/50) and 0.52 (20/67) for IVI versus IVI/PDT groups, respectively (P = 0.33), and in year 10 was 0.53 (20/58) and 0.64 (20/86), respectively (P = 0.50). The average number of annual injections over the first 5 years of follow-up was 3.3 versus 1.7 for IVI versus IVI/PDT groups, respectively (P < 0.001), and over 10 years was 3.3 versus 1.6, respectively (P < 0.001). Treatment-free interval of 5 years was reached by 39% versus 60% in IVI versus IVI/PDT groups, respectively (P = 0.95). Conclusion: Our study found both IVI and IVI/PDT to be effective in long-term management of presumed ocular histoplasmosis syndrome choroidal neovascularization, with a fewer number of annual injections and longer treatment-free interval in the combination group. However, given the limitations of a retrospective study, a prospective randomized study is necessary to determine whether the addition of PDT significantly decreases treatment burden.

1 April 2022 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
KBKimberly D. Blankshain
Kimberly D. Blankshain
MSMichael E. Snyder
Michael E. Snyder
DMDaniel M. Miller
Daniel M. Miller
AKAnup K. Khatana
Anup K. Khatana

15 October 2026 in Ophthalmology Retina
Verified
Journal Article
Closed access
DHDenis Huang
Denis Huang
JFJack E. Feist
Jack E. Feist
SMSloane A. McTavish
Sloane A. McTavish
MKMuhammad Jehanzeb Khan
Muhammad Jehanzeb Khan
RSRobert A. Sisk
Robert A. Sisk
CRChristopher D. Riemann
Christopher D. Riemann